NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a national shareholder and consumer rights litigation firm, is investigating whether Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO) or certain of its officers and directors violated federal securities laws. If you purchased Inovio stock on or after March 3, 2020, you are encouraged to contact Scott+Scott attorney Jonathan Zimmerman for additional information at (888) 398-9312 or firstname.lastname@example.org for more information.
On March 3, 2020, Inovio announced “an accelerated timeline for developing its DNA vaccine INO-4800.” The Company’s CEO said that, “[u]sing our modern DNA medicines platform, we designed our DNA vaccine INO-4800 in three hours after the publication of the genetic sequence of the novel coronavirus that causes COVID-19.” After this announcement, the Company’s stock price skyrocketed.
Then, on March 9, 2020, Citron Research issued a report on the Company, claiming that the Company had made a “ludicrous and dangerous claim that they designed a vaccine in 3 hours.”
As of this writing, Inovio’s stock price is down approximately 37% on this news.
What You Can Do
If you purchased Inovio stock on or after March 3, 2020, and you wish to discuss this investigation, you are encouraged to contact attorney Jonathan Zimmerman at (888) 398-9312 or email@example.com, or visit the Inovio investigation page on our website at https://scott-scott.com/investigation/inovio-pharmaceuticals-inc/.
About Scott+Scott Attorneys at Law LLP
Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.